Summary of conventional chemotherapeutic agents that have been tested in combination with imatinib in vitro.*
| Combined Drug . | Synergy . | Additivity . | Antagonism . |
|---|---|---|---|
| *Included are all published results in the studies of Topaly et al,38 Thiesing et al,32 and Kano et al.34 Joint action studies were performed using myeloid or lymphoid chronic myelogenous leukemia (CML) blast crisis cell lines or using Bcr-Abl-negative cell lines with engineered Bcr-Abl expression. | |||
| Ara-C | ✓ | ||
| Carboplatin | ✓ | ||
| Corticosteroids | ✓ | ||
| Etoposide | ✓ | ||
| Idarubicin | ✓ | ||
| Interferon (IFN) | ✓ | ✓ | |
| Mafosfamide | ✓ | ||
| Mitoxantrone | ✓ | ||
| Treosulfan | ✓ | ||
| Vincristine | ✓ | ||
| Nimustine hydrochloride | ✓ | ||
| Busulfan | ✓ | ||
| 4-OH-cyclophosphamide | ✓ | ||
| Daunorubicin | ✓ | ||
| Doxorubicin | ✓ | ||
| Fludarabine | ✓ | ||
| Gemcitabine | ✓ | ||
| Taxotere | ✓ | ||
| Thiotepa | ✓ | ||
| Cladribine | ✓ | ||
| Hydroxyurea | ✓ | ✓ | |
| Methotrexate | ✓ | ||
| Topotecan | ✓ | ||
| Combined Drug . | Synergy . | Additivity . | Antagonism . |
|---|---|---|---|
| *Included are all published results in the studies of Topaly et al,38 Thiesing et al,32 and Kano et al.34 Joint action studies were performed using myeloid or lymphoid chronic myelogenous leukemia (CML) blast crisis cell lines or using Bcr-Abl-negative cell lines with engineered Bcr-Abl expression. | |||
| Ara-C | ✓ | ||
| Carboplatin | ✓ | ||
| Corticosteroids | ✓ | ||
| Etoposide | ✓ | ||
| Idarubicin | ✓ | ||
| Interferon (IFN) | ✓ | ✓ | |
| Mafosfamide | ✓ | ||
| Mitoxantrone | ✓ | ||
| Treosulfan | ✓ | ||
| Vincristine | ✓ | ||
| Nimustine hydrochloride | ✓ | ||
| Busulfan | ✓ | ||
| 4-OH-cyclophosphamide | ✓ | ||
| Daunorubicin | ✓ | ||
| Doxorubicin | ✓ | ||
| Fludarabine | ✓ | ||
| Gemcitabine | ✓ | ||
| Taxotere | ✓ | ||
| Thiotepa | ✓ | ||
| Cladribine | ✓ | ||
| Hydroxyurea | ✓ | ✓ | |
| Methotrexate | ✓ | ||
| Topotecan | ✓ | ||